Amgen Inc. (AMGN) Stock Analysis 2026

Amgen is one of the world's largest biotechnology companies, focused on developing therapies in oncology, cardiovascular, bone health, inflammation, and neuroscience. The company's blockbuster drugs include Repatha (cholesterol), Prolia/Xgeva (bone), Enbrel (inflammation), and the obesity drug MariTide (in development). Amgen's $27.8B acquisition of Horizon Therapeutics (2023) added rare disease therapies including Tepezza (thyroid eye disease). Amgen's obesity pipeline (MariTide) has made it a dark horse in the GLP-1 weight loss race.

This chart shows how Amgen's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Amgen Inc. trades at a trailing P/E of 23.42x, generates $8.65B in free cash flow, runs a debt/equity ratio of 490.28, and converts shareholder equity into profit at a 91.5% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

28 analysts covering Amgen Inc. currently lean toward a Hold rating, with a mean 12-month price target of $388.03 (+0.6% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 4 valuation models to estimate AMGN's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

AMGN is currently in a short-term downtrend, trading below its 50-day average of $399.10 and above its 200-day average of $359.37. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

AMGN's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.